thanks for thati was just looking at the vol by price seems...

thanks for that
i was just looking at the vol by price seems accumulation levels are higher...




just holding 30c
In todays top 20 traded up to 33c

off the anncmt 1050am

Signs Exclusive Patent Deal

BRESAGEN LIMITED 2003-05-29 ASX-SIGNAL-G

HOMEX - Adelaide

+++++++++++++++++++++++++
In a deal which will significantly enhance its protein pharmaceutical
business, BresaGen Ltd today announced that it has signed an
exclusive licensing agreement for a suite of seven patent
applications covering production methods for recombinant proteins and
peptides.

The Adelaide-based biotechnology company negotiated the agreement
with Restoragen, Inc, a Nebraska-based company which has been
developing commercially viable methods for the recombinant production
of peptides.

It is a significant investment and reinforces BresaGen's strategy to
exploit the worldwide shortage of protein manufacturing capacity,
with a particular emphasis on the niche of peptide based
pharmaceuticals.

The Intellectual Property (IP) covers a variety of methods for
manufacturing large quantities of clinical-grade middle-range
peptides (10-100 amino acids in length) while maintaining exceptional
purity.

Included in the package are methodologies for molecular engineering,
optimisation of highyield fermentation, and robust downstream
processing. Together, these methods provide a proprietary molecular
toolbox which can be tailored and optimised for each specific
peptide.

BresaGen Chief Operating Officer, Dr Meera Verma, said "The
elucidation of the human genome has brought with it a worldwide
increase in proteins and peptides to fill the drug candidate
pipeline, creating new opportunities for protein pharmaceutical
manufacturing.

The Restoragen technology is a key acquisition which will add to our
existing toolkit of proprietary methods and established expertise to
give BresaGen a significant advantage in this growing business."

Professor Fred Wagner, who developed a number of the methodologies in
the Restoragen patent suite, will act as a consultant to BresaGen,
seeking new partners for BresaGen in the USA.

BresaGen currently has contracts with Metabolic Pharmaceuticals,
Australian Cancer Technology and other Australian biotechnology
companies for process development or manufacture of various protein
pharmaceutical candidates.

For further information contact:

Dr Jackie Zanetti
Business Development Manager
BresaGen Ltd
Phone: 08 81508208
Mobile: 0439 805832

Hilarie Dunn
Media Relations for BresaGen
Hilarie Dunn & Associates
Phone: 02 92510110
Mobile: 0414 357792